| P50 | author | Laurence Bindoff | Q42402608 |
| | Kjetil Bjornevik | Q56912391 |
| | Øivind Torkildsen | Q57012585 |
| | Christian Barro | Q60690467 |
| | Kjell-Morten Myhr | Q64539690 |
| | Christian A Vedeler | Q89449121 |
| | Stig Wergeland | Q114371118 |
| P2093 | author name string | Jens Kuhle | |
| | Kristin N Varhaug | |
| P2860 | cites work | Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis | Q28257420 |
| | Neurofilament in CSF-A biomarker of disease activity and long-term prognosis in multiple sclerosis | Q28276772 |
| | Axonal transection in the lesions of multiple sclerosis | Q29615585 |
| | Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis | Q35537489 |
| | Neurofilament light chain: a biomarker for genetic frontotemporal dementia | Q37208495 |
| | ω-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial | Q38473197 |
| | Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis | Q38682945 |
| | Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome | Q39035274 |
| | Label-free analysis of human cerebrospinal fluid addressing various normalization strategies and revealing protein groups affected by multiple sclerosis. | Q40027938 |
| | Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. | Q40864697 |
| | Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes | Q41422799 |
| | Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients | Q41462389 |
| | Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. | Q44028578 |
| | Monoclonal antibodies selective for low molecular weight neurofilaments. | Q47186756 |
| | Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. | Q48269484 |
| | Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases | Q48682038 |
| | Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity. | Q49015259 |
| | Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. | Q50965805 |
| | Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis. | Q51210251 |
| | Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis. | Q51359685 |
| | Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod. | Q53212006 |
| | Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis. | Q53624114 |
| | Chitinase 3-like 1 plasma levels are increased in patients with progressive forms of multiple sclerosis | Q56999356 |
| | Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis | Q86613307 |
| | Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis | Q86777868 |
| P433 | issue | 1 | |
| P304 | page(s) | e422 | |
| P577 | publication date | 2017-11-28 | |
| P1433 | published in | Neurology(R) neuroimmunology & neuroinflammation | Q27725776 |
| P1476 | title | Neurofilament light chain predicts disease activity in relapsing-remitting MS | |
| P478 | volume | 5 | |